Reports Q4 revenue $18.01M, consensus $17.46M. “This is an exciting period in our Company’s history as we grew total revenue by 44% in 2023, which was driven by the execution of our strategy to expand market usage of our RNS System, while maintaining financial discipline and reducing our cash burn to $3.4 million in the fourth quarter,” said Joel Becker, CEO of NeuroPace. “In 2023, we successfully implemented the first part of our three-part growth strategy for developing the market for our RNS System, aimed at increasing adoption across clinicians and expanding therapy utilization by current prescribers under what we call the ‘modern RNS story.’ We also successfully integrated DIXI Medical SEEG electrodes into our product portfolio and expanded sales throughout the year.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NPCE:
- NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million
- NPCE Earnings this Week: How Will it Perform?
- NeuroPace price target raised to $16 from $9 at Wells Fargo
- NeuroPace to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
- NeuroPace Announces Chief Legal Officer Irina Ridley’s Departure